MHRA grants marketing authorisation for Global Blood Therapeutics’s Oxbryta
Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation
Read More
Tag: Oxbryta
EMA begins review of GBT’s sickle cell treatment Oxbryta
GBT is aiming for the approval of Oxbryta to treat haemolytic anaemia in patients with sickle cell disease
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
